June 20, 2022
Taisho Pharmaceutical on June 17 launched an orally disintegrating (OD) film sheet version of its SGLT2 inhibitor Lusefi (luseogliflozin) for the treatment of type 2 diabetes. The new version, which is expected to boost convenience and improve drug adherence for...read more